Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Alignment Healthcare has clawed back 9.7% over the past week to $8.28, a welcome reprieve after a catastrophic October. The stock remains down 20% over the past month and the October 29 earnings print, now eleven days away, is shaping up as the make-or-break moment of the year.
Options positioning captures the shift in mood most clearly. The put/call ratio has dropped sharply to 0.30, roughly 1.6 standard deviations below its 20-day average of 0.48. That is a notably bullish tilt: calls are dominating over puts, which aligns with the week's price recovery but stands in some tension with the fundamental damage done by last week's wave of analyst cuts. The PCR hit a 20-day low, reversing from readings above 0.60 that persisted through late September and into early October. Buyers of upside optionality appear to be betting the selloff has run its course ahead of earnings. Short interest, meanwhile, climbed 8.3% over the week to 12.5% of the free float, around 25 million shares, with the bulk of the build arriving between October 8 and October 9. Borrow remains cheap at 0.42% and availability is loose at 677%, about six shares available for every one already borrowed. That combination tells the same story as the options skew: shorts are rebuilding positions but there is no squeeze risk, and the lending market is relaxed.
The Street remains deeply scarred. Since the previous note on October 10, UBS has added to the damage, cutting its target from $22 to $9 while holding a Neutral rating, the most aggressive percentage cut of the cycle. TD Cowen trimmed from $21 to $12 while keeping a Buy. JP Morgan, which had already slashed to $10, is now among the more constructive voices by default given the stock is trading at $8.28. The consensus mean target is $13.31, which implies meaningful upside on paper, but every price target in the data was set before the stock fell through $10, and the direction of travel for the past several weeks has been one of continuous resets. EPS momentum over the last 30 days ranks in the fifth percentile of the ORTEX universe. The analyst recommendation divergence score ranks just first percentile, reflecting how wide the gap has grown between the formal ratings and where the stock actually trades. Bulls still point to the Stars-funded Medicare Advantage model and the 2026 rate environment as structural tailwinds. Bears worry about PCP performance inconsistencies and payor data friction, and the July earnings reaction, a one-day drop of 18.8% followed by a further 26.8% over five days, gives that bearish case considerable weight in the market's memory.
Insider activity has been uniformly negative, though the interpretation requires some care. The CEO, John Kao, sold shares on three occasions between August 10 and September 11 at prices ranging from $12.68 to $13.88, all under pre-arranged 10b5-1 plans, which diminishes the signal value. The President, Dawn Maroney, sold $1.56 million worth of shares on September 11 outside any declared plan, a more telling data point. The Chief Medical Officer sold $270,000 on October 6 without a plan. Net insider selling over the past 90 days totals around 1.5 million shares, worth roughly $23.3 million. There have been no open-market purchases. The picture is not one of executives seizing on weakness to buy; it is one of consistent distribution at every price point from $20 down to $8.
On the institutional side, BlackRock raised its stake to 11.3% of shares, as disclosed in a 13G/A filed October 5, up from 9.1% previously. That is the most recent significant ownership development and adds a degree of heavyweight passive support to the register. Qatar Investment Authority holds 6.4% as of its September 2025 disclosure, though that figure is now over a year old and, as with all 13D/G filings, should be treated as the position at time of last disclosure rather than a current reading.
The next print on October 29 is the event that matters. The previous quarter produced the worst single-day reaction in recent memory. The question for the coming eleven days is whether the options market's shift toward calls reflects genuine stabilisation or simply a short-term bounce within a longer deterioration.
See the live data behind this article on ORTEX.
Open ALHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
